Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning

(2011) Jennifer R. Smith et al.   CELL CYCLE

Shape Effect of Carbon Nanovectors on Angiogenesis

(2010) Padmaparna Chaudhuri et al.   ACS Nano

Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo

(2010) Phan LCHB Tran et al.   BMC CANCER

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

(2010) Warren Fiskus et al.   CANCER BIOLOGY & THERAPY

Hyperthermia-associated carboplatin resistance: Differential role of p53, HSF1 and Hsp70 in hepatoma cells

(2010) Aanchal Sharma et al.   CANCER SCIENCE

Untangling the unfolded protein response

(2010) Emma L. Davenport et al.   CELL CYCLE

Heat shock proteins as targets in oncology

(2010) Alejandra Giménez Ortiz et al.   Clinical & Translational Oncology

New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

(2010) T. Nakashima et al.   CLINICAL CANCER RESEARCH

Novel therapeutic targets for multiple myeloma

(2010) Anuj Mahindra et al.   Future Oncology

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

(2010) Joleen Hubbard et al.   INVESTIGATIONAL NEW DRUGS

Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity

(2010) Anne-Laure Joly et al.   Journal of Innate Immunity

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells

(2010) Chun Hei Antonio Cheung et al.   Molecular Cancer

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

(2010) Diana Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

Hsp90: A Drug Target?

(2010) Jeffrey M. Holzbeierlein et al.   Current Oncology Reports

Modulation of Hsf1 activity by novobiocin and geldanamycin

(2009) Renaud Conde et al.   Biochemistry and Cell Biology

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

(2009) J. Qian et al.   BLOOD

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

(2009) Sagar Lonial et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800

(2009) Thorsten Stühmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Future Novel Single Agent and Combination Therapies

(2009) Diana Cirstea et al.   CANCER JOURNAL

Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance

(2009) C. Wong et al.   CANCER RESEARCH

Transcription Inhibition of Heat Shock Proteins: A Strategy for Combination of 17-Allylamino-17-Demethoxygeldanamycin and Actinomycin D

(2009) F. Cervantes-Gomez et al.   CANCER RESEARCH

17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside

(2009) Saad Usmani et al.   CURRENT MOLECULAR MEDICINE

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

(2009) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

To fold or not to fold: modulation and consequences of Hsp90 inhibition

(2009) Laura B Peterson et al.   Future Medicinal Chemistry

Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma

(2009) Marco Breinig et al.   HEPATOLOGY

Activation of natural killer cells by heat shock protein 70

(2009) Gabriele Multhoff   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70

(2009) Yufeng Xie et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Proteomic and Functional Analyses Reveal a Dual Molecular Mechanism Underlying Arsenic-Induced Apoptosis in Human Multiple Myeloma Cells

(2009) Feng Ge et al.   JOURNAL OF PROTEOME RESEARCH

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas

(2009) Leandro C Cerchietti et al.   NATURE MEDICINE

Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression

(2009) M. Tariq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

(2009) Constantine S. Mitsiades et al.   SEMINARS IN HEMATOLOGY

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

(2008) Y. Okawa et al.   BLOOD

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications

(2008) Kenji Ishitsuka et al.   BRITISH JOURNAL OF HAEMATOLOGY

HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma

(2008) Ramadevi Nimmanapalli et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and In vivo Study

(2008) A. S. Martins et al.   CANCER RESEARCH

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

(2008) Pascale Flandrin et al.   CELL STRESS & CHAPERONES

New insights into the mechanism of heat shock response activation

(2008) I. Shamovsky et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers

(2008) S. Chandarlapaty et al.   CLINICAL CANCER RESEARCH

Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment

(2008) A. Huston et al.   CLINICAL CANCER RESEARCH

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

(2008) A. N. Tse et al.   CLINICAL CANCER RESEARCH

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

(2008) S. S. Ramalingam et al.   CLINICAL CANCER RESEARCH

Heat Shock Protein 90 as a Drug Target: Some Like It Hot

(2008) U. Banerji   CLINICAL CANCER RESEARCH

Targeting Hsp90: small-molecule inhibitors and their clinical development

(2008) Tony Taldone et al.   CURRENT OPINION IN PHARMACOLOGY

Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines

(2008) Joseph A. Burlison et al.   JOURNAL OF ORGANIC CHEMISTRY

A Cremophor-Free Formulation for Tanespimycin (17-AAG) Using PEO-b-PDLLA Micelles: Characterization and Pharmacokinetics in Rats

(2008) May P. Xiong et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo

(2008) M A Shammas et al.   LEUKEMIA

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

(2008) T Stühmer et al.   LEUKEMIA

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

(2008) J R Smith et al.   ONCOGENE

Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?

(2008) Paolo Decuzzi et al.   PHARMACEUTICAL RESEARCH

HSP90/70 chaperones are required for rapid nucleosome removal upon induction of the GAL genes of yeast

(2008) M. Floer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The effect of particle design on cellular internalization pathways

(2008) S. E. A. Gratton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA